Tharimmune (THAR) Competitors $3.16 -0.02 (-0.63%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$3.14 -0.02 (-0.76%) As of 05:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock THAR vs. CRVO, BYSI, PMVP, RLMD, ARTV, ATYR, ABVC, CLNN, HYPD, and CVMShould you be buying Tharimmune stock or one of its competitors? The main competitors of Tharimmune include CervoMed (CRVO), BeyondSpring (BYSI), PMV Pharmaceuticals (PMVP), Relmada Therapeutics (RLMD), Artiva Biotherapeutics (ARTV), aTyr Pharma (ATYR), ABVC BioPharma (ABVC), Clene (CLNN), Hyperion DeFi (HYPD), and CEL-SCI (CVM). These companies are all part of the "pharmaceutical products" industry. Tharimmune vs. Its Competitors CervoMed BeyondSpring PMV Pharmaceuticals Relmada Therapeutics Artiva Biotherapeutics aTyr Pharma ABVC BioPharma Clene Hyperion DeFi CEL-SCI CervoMed (NASDAQ:CRVO) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment. Is CRVO or THAR more profitable? Tharimmune has a net margin of 0.00% compared to CervoMed's net margin of -290.72%. CervoMed's return on equity of -59.15% beat Tharimmune's return on equity.Company Net Margins Return on Equity Return on Assets CervoMed-290.72% -59.15% -53.64% Tharimmune N/A -1,239.20%-365.06% Do institutionals & insiders have more ownership in CRVO or THAR? 25.2% of CervoMed shares are held by institutional investors. Comparatively, 1.2% of Tharimmune shares are held by institutional investors. 35.4% of CervoMed shares are held by insiders. Comparatively, 25.6% of Tharimmune shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk and volatility, CRVO or THAR? CervoMed has a beta of -0.84, meaning that its share price is 184% less volatile than the S&P 500. Comparatively, Tharimmune has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Does the media prefer CRVO or THAR? In the previous week, CervoMed had 4 more articles in the media than Tharimmune. MarketBeat recorded 10 mentions for CervoMed and 6 mentions for Tharimmune. CervoMed's average media sentiment score of 0.88 beat Tharimmune's score of 0.86 indicating that CervoMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CervoMed 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tharimmune 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate CRVO or THAR? CervoMed presently has a consensus price target of $19.29, suggesting a potential upside of 125.83%. Tharimmune has a consensus price target of $17.00, suggesting a potential upside of 437.97%. Given Tharimmune's stronger consensus rating and higher probable upside, analysts clearly believe Tharimmune is more favorable than CervoMed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CervoMed 2 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.60Tharimmune 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Which has higher valuation and earnings, CRVO or THAR? Tharimmune has lower revenue, but higher earnings than CervoMed. CervoMed is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCervoMed$9.74M8.11-$16.29M-$2.61-3.27TharimmuneN/AN/A-$12.20M-$6.10-0.52 SummaryCervoMed beats Tharimmune on 9 of the 15 factors compared between the two stocks. Get Tharimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding THAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THAR vs. The Competition Export to ExcelMetricTharimmuneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.77M$3.36B$6.14B$10.64BDividend YieldN/A2.29%5.66%4.69%P/E Ratio-0.5221.3485.7227.64Price / SalesN/A487.79631.45142.60Price / CashN/A47.1938.3262.20Price / Book4.6510.4313.096.79Net Income-$12.20M-$52.40M$3.30B$275.88M7 Day Performance8.59%4.97%3.75%1.84%1 Month Performance3.61%17.02%10.73%8.84%1 Year Performance54.90%34.38%85.28%36.10% Tharimmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THARTharimmune2.495 of 5 stars$3.16-0.6%$17.00+438.0%+56.4%$18.77MN/A-0.522News CoverageAnalyst ForecastCRVOCervoMed3.7201 of 5 stars$8.03-0.7%$19.29+140.2%-33.4%$74.30MN/A-3.084News CoverageAnalyst ForecastGap UpBYSIBeyondSpringN/A$1.79-1.1%N/A-26.7%$72.19MN/A0.0080News CoverageAnalyst ForecastGap DownPMVPPMV Pharmaceuticals3.3336 of 5 stars$1.36-2.9%$5.50+304.4%-6.7%$72.07MN/A-0.8750Positive NewsRLMDRelmada Therapeutics2.7685 of 5 stars$2.16+7.5%$1.00-53.7%-35.3%$71.70MN/A-0.9710Positive NewsAnalyst ForecastARTVArtiva Biotherapeutics3.348 of 5 stars$2.92+1.7%$17.00+482.2%-79.8%$71.32MN/A0.0081News CoveragePositive NewsAnalyst ForecastATYRaTyr Pharma3.2072 of 5 stars$0.69-4.3%$23.25+3,267.6%-54.8%$70.69MN/A-0.8653Analyst ForecastInsider TradeHigh Trading VolumeABVCABVC BioPharma0.8617 of 5 stars$2.99-1.6%N/A+512.3%$70.39M$391.24K-17.5930Analyst ForecastCLNNClene3.2166 of 5 stars$6.97+15.6%$32.60+367.7%+61.4%$70.19M$286K-1.85100Positive NewsShort Interest ↑High Trading VolumeHYPDHyperion DeFi0.4891 of 5 stars$9.94+3.8%$2.00-79.9%-76.7%$69.17M$44.44K-0.1740Analyst ForecastCVMCEL-SCIN/A$9.94+8.0%N/AN/A$68.41MN/A-20.7143 Related Companies and Tools Related Companies CervoMed Competitors BeyondSpring Competitors PMV Pharmaceuticals Competitors Relmada Therapeutics Competitors Artiva Biotherapeutics Competitors aTyr Pharma Competitors ABVC BioPharma Competitors Clene Competitors Hyperion DeFi Competitors CEL-SCI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:THAR) was last updated on 10/10/2025 by MarketBeat.com Staff From Our Partners"I'm risking my reputation on this"The Fed rate cut truth they don't want you to know The Fed's 25 basis point cut isn't just monetary policy…...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredTrump to get REVENGE on the banks??Rumors are swirling that Trump could target the banking system by upending the $5 trillion-a-day SWIFT network...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tharimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tharimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
